Oxford Asset Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-49,811
| Closed | -$720K | – | 467 |
|
|
2026
Q1 | $720K | Sell |
49,811
-118,703
| -70% | -$1.7M | 0.29% | 92 |
|
|
2025
Q4 | $2.4M | Buy |
168,514
+141,899
| +533% | +$1.39M | 0.85% | 7 |
|
|
2025
Q3 | $210K | Sell |
26,615
-13,905
| -34% | -$99K | 0.07% | 380 |
|
|
2025
Q2 | $232K | Buy |
+40,520
| New | +$262K | 0.08% | 396 |
|
|
2024
Q3 | – | Sell |
-19,099
| Closed | -$189K | – | 356 |
|
|
2024
Q2 | $189K | Buy |
+19,099
| New | +$196K | 0.18% | 214 |
|
|
2020
Q1 | – | Sell |
-147,903
| Closed | -$1.44M | – | 613 |
|
|
2019
Q4 | $1.44M | Buy |
+147,903
| New | +$1.35M | 0.04% | 623 |
|
|
2019
Q2 | – | Sell |
-36,473
| Closed | -$496K | – | 1795 |
|
|
2019
Q1 | $496K | Buy |
+36,473
| New | +$446K | 0.01% | 1222 |
|
|
2018
Q2 | – | Sell |
-83,777
| Closed | -$1.26M | – | 1773 |
|
|
2018
Q1 | $1.26M | Buy |
+83,777
| New | +$1.27M | 0.03% | 822 |
|
|
2016
Q1 | – | Sell |
-614,976
| Closed | -$5.96M | – | 834 |
|
|
2015
Q4 | $5.96M | Buy |
+614,976
| New | +$5.54M | 0.14% | 149 |
|
|
2015
Q2 | – | Sell |
-458,701
| Closed | -$4.99M | – | 683 |
|
|
2015
Q1 | $4.99M | Buy |
458,701
+181,816
| +66% | +$1.6M | 0.13% | 182 |
|
|
2014
Q4 | $2.28M | Buy |
276,885
+263,616
| +1,987% | +$1.81M | 0.05% | 355 |
|
|
2014
Q3 | $79K | Buy |
+13,269
| New | +$69.5K | ﹤0.01% | 651 |
|
|
2014
Q2 | – | Sell |
-104,166
| Closed | -$216K | – | 722 |
|
|
2014
Q1 | $216K | Buy |
+104,166
| New | +$260K | 0.01% | 590 |
|
Other funds holding FOLD
Oxford Asset Management's FOLD Position: Q2 2026 in Review
Oxford Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 49,811 shares — an estimated $720K sold.
Oxford Asset Management first reported a position in FOLD in Q1 2014 and held it in 13 quarters. The position peaked at $5.96M in Q4 2015. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Oxford Asset Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Oxford Asset Management sold 49,811 Amicus Therapeutics shares in Q2 2026, an estimated $720K.
- Oxford Asset Management first reported a position in Amicus Therapeutics in Q1 2014 and held it in 13 quarters.
- Oxford Asset Management's Amicus Therapeutics position peaked at $5.96M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.